Hints and tips:
Related Topics
...A few years ago a pharma analyst fretted to me that “there are no blockbuster drugs left to discover”. Pharma groups had sunk billions into treatments that did not work....
...“At the same time the world’s big pharma and technology companies are coming here to make use of our genomics environment and plug into our data sets.”...
...Oxford BioMedica has manufactured over 100mn doses since it went into partnership with the pharma heavyweight, with orders accelerating through the second half of 2021....
...Losing the pharma licence might limit SpectrumX to hand gels and detox tunnels....
...“It’s the biggest vaccine programme in history and the logistics are enormous,” said Dr Nigel Watson, chief executive of the Wessex Local Medical Committees....
...Big Pharma Some big participants in the pharmaceutical sector will be watched closely by analysts this week as they publish their results....
...The attempt to oust the deputy leader Tom Watson was clumsy, vindictive, and exposed the faultlines that still run across the party....
...“They will break down the barriers between pharma and device companies, and between doctors, hospitals and patients.”...
...(“Chevron: the elemental Watson”, FT.com, August 24). Yes, but perhaps for more broad-based reasons than many may perceive. Three material threats face any mature company....
...The FCA referred the sector to the antitrust body over fears that the largest consultants — Aon Hewitt, Mercer and Willis Towers Watson, which collectively control up to 80 per cent of the British market...
...It is still early days for big pharma’s digital push....
...(Newsweek) Cancer claims IBM pitched its Watson supercomputer as a real breakthrough in cancer care but a report suggests the company failed to fully assess the challenges of deploying it in hospitals....
...However, Graham Watson, partner at Freshfields Bruckhaus Deringer, the London-based law firm, says it is the relative stability of prices over the past year, rather than the partial recovery, that has been...
...Companies due to deliver results today include: Taylor Wimpey, Interserve, St James’ Place, Virgin Money and Jazz Pharma....
...Such a transaction would continue the company’s three-year dealmaking spree, which has taken it from a run-of-the-mill generic drugmaker known as Watson Pharmaceuticals, with a market capitalisation of $8bn...
...The distribution of multinationals’ drug products is monopolised in the Philippines by Zuellig Pharma and its affiliate Metro Drug....
...Partner, SV Life Sciences Allan Malcolm Business Development Manager, Synergy Health Dr David Venables Chief Executive, Synpromics Adam Zaeske General Manager, Takeda Pharmaceuticals Dr William Watson...
...Consultants such as Watson Wyatt’s Roger Urwin have had the power to make or break the careers of institutional investment managers....
...to one of the world’s biggest pharma groups....
...It also invested $800m in Gilead Sciences, a US pharma company which is developing tailored therapies for cancer. The current year’s investment strategy looks set to be more cautious....
...His rise to the pharma big league has been swift....
...In 2012, the group, then called Watson, was a run-of-the-mill producer of generic drugs with a market capitalisation of $8bn — a fraction of the $120bn it is worth today....
...It is more than two years since Watson, now called Actavis, embarked on a multiyear acquisition spree that saw it go from a copycat drugmaker with a market capitalisation of $8bn to a top 10 pharmaceutical...
...“The goal is to keep the population healthy by spending more money on early intervention,” says David Watson, chief executive of Cal Index, a Californian ACO database....
...There was no grand plan to catapult the company into the top tier of pharma companies....
International Edition